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Available online 21 March 2016AbstractAim: This Clinical Guidance is aimed to help practitioners assess, diagnose and manage their patients with osteoporosis (OP), using the best
available evidence.
Methods: A literature search using PubMed (MEDLINE) and The Cochrane Library identified all relevant articles on OP and its assessment,
diagnosis and treatment, from 2011, to update from the 2012 edition. The studies were assessed and the level of evidence assigned. For each
statement, studies with the highest level of evidence were used to frame the recommendation.
Results: This article summarizes the diagnostic and treatment pathways for postmenopausal and male OP, while addressing the risk-benefit ratio
for OP treatment. Recognising the limitation of only depending on bone mineral density in assessing fracture risk, a move to assess 10 year
fracture risk using tools such as FRAX, is recommended as a guide to decision-making on when to start treatment. A re-evaluation was done of
the position of calcium supplementation and on the importance of vitamin D. There has been concern about the potential adverse effects of the
long-term usage of bisphosphonates, which have been discussed fully. Algorithms for the management of postmenopausal and male OP have
been updated.
Conclusions: Adequate intake of calcium (1000 mg from both diet and supplements) and vitamin D (800 IU) daily remain important adjuncts in
the treatment of OP. However, in confirmed OP, pharmacological therapy with anti-resorptives is the mainstay of treatment in both men and
postmenopausal women. Patients need to be regularly assessed while on medication and treatment adjusted as appropriate.
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Table 2
Indications for BMD Measurementa
1. All women aged 65 and above and men aged 70 and above [8]
2. Presence of strong risk factors
Estrogen deficiency
 Premature menopause (<45 years of age) including surgical menopause
 Prolonged secondary amenorrhoea
 Hypogonadism
2 S.S. Yeap et al. / Osteoporosis and Sarcopenia 2 (2016) 1e121. Introduction
Osteoporosis (OP) is a systemic skeletal disease charac-
terised by low bone mass and micro-architectural deterioration
of bone tissue, with a consequent increase in bone fragility and
susceptibility to fracture [1]. Epidemiological studies have
estimated that there would be an exponential increase in the
incidence of osteoporotic fractures in Asia, so that by 2050,
50% of all hip fractures would occur in this region [2]. In
Malaysia, in 1997, the incidence of hip fracture among in-
dividuals above 50 years of age was 90 per 100,000 population
[3]. The incidence increased with age; in the 50e54 year olds,
the incidence was 10 per 100,000, rising to 510 per 100,000 in
those over 75 years old [3]. Malaysia still has a predominantly
young population, with only 5.5% (~1.6 million) of its esti-
mated 30 million populace above the age of 65 years. However,
the life expectancy of Malaysians is increasing; it is 77.4 years
for women and 72.5 years for men.With this ageing population,
the burden of OP is expected to continue to rise in Malaysia.
The Malaysian Osteoporosis Society (MOS) had previously
published Clinical Practice Guidelines in the Management of
OP in 2001, 2006 and 2012, which aimed at providing a
framework to assist doctors in the diagnosis and management
of osteoporosis without restricting the physician's individual
judgement. Following the 2012 edition, there were further data
and studies, in the controversial area of calcium supplemen-
tation, bisphosphonate side effects (atypical femoral fractures
and osteonecrosis of the jaw), and the place of hormone
replacement therapy and strontium in the OP therapeutic
armamentarium. Although other guidelines are available, this
guidance was written in the context of a developing country
such as Malaysia, taking into account the healthcare resources
available locally. This guidance provides a review of the
therapeutic agents available for the treatment of osteoporosis,
with the aim of reducing fracture, and its accompanying
morbidity and mortality.
2. Methods
The previous Clinical Practice Guidelines published in
2012 was used as the baseline. To update the document, aTable 1
Risk Factors for Osteoporosis and Fracture [Adapted from reference 6]
Non-modifiable
1. Advancing age
2. Ethnic group
(Oriental & Caucasian)
3. Female gender
4. Premature menopause
(<45 years)
including surgical
menopause
5. Family history of
osteoporosis or fracture
in first degree relative
6. Personal history of
fracture as an adult
Modifiable
1. Low calcium and/or vitamin D intake
2. Sedentary lifestyle
3. Cigarette smoking
4. Alcohol intake of more than 3 units daily
5. Caffeine intake of more than
330 mg daily (more than 3 cups daily)
6. Low body weight (BMI < 19 kg/m2)
7. Estrogen deficiency
8. Frequent fallssystematic review and literature search by the members of the
Working Group, using PubMed (MEDLINE) and The
Cochrane Library, identified all relevant articles on OP and its
assessment, diagnosis and treatment, from 2011 to 2015. The
date 2011 rather than 2012 was chosen so that all studies
published just before and after the last guidelines would be
reviewed and none inadvertently overlooked. The studies were
assessed and graded with the levels of evidence as used by the
National Guideline Clearinghouse, Agency for Healthcare
Research and Quality, U.S. Department of Health & Human
Services, USA [4] (Appendix 1). For each statement, studies
with the highest levels of evidence were used to frame the
statements. The grade of recommendation was taken from the
Scottish Intercollegiate Guidelines Network grading system
[5] (Appendix 1).3. Results and discussion3.1. The diagnosis of OPThe traditional risk factors, as shown in Table 1 (adapted
from Ref. [6]), are still useful in identifying subjects at risk of
OP and fracture (case finding) (Grade C, Level IV). The
Osteoporosis Self-Assessment Tool for Asians (OSTA) is a
simple table based on age and weight that can identify women
who may be at high risk of OP who then may require a bone
mineral density (BMD) measurement [7] (Grade B, Level III).
The best method of assessing BMD is using dual-energy x-ray
absorptiometry (DXA) at the lumbar spine and hip. General
screening of the population is not recommended; the excep-
tions being women over the age of 65 and men over the age ofGlucocorticoid therapy
Maternal family history of hip fracture
Low body mass index (<19 kg/m2)
Other conditions associated with osteoporosis
 Anorexia nervosa
 Malabsorption
 Hyperparathyroidism
 Hyperthyroidism
 Prolonged immobilisation
 Cushing's syndrome
 Post-bariatric surgical bypass
 Drugs (e.g. aromatase inhibitors, GnRH agonists)
3. Radiological osteopenia and/or vertebral deformity
4. Previous low trauma fractures of hip, spine and/or wrist
5. Loss of height, thoracic kyphosis
6. Low weight for age (OSTAb) for postmenopausal women [7] (Appendix 2)
a BMD should only be measured in subjects who are willing to consider
available interventions.
b OSTA ¼ Osteoporosis Self-assessment Tool for Asians.
3S.S. Yeap et al. / Osteoporosis and Sarcopenia 2 (2016) 1e1270 [8] (Grade C, Level IV). Table 2 shows the indications for
BMD measurement.
Based on the World Health Organisation working group, OP
can be diagnosed when the BMD value is 2.5 SD or more below
the young adult mean (T-score  2.5), using a central DXA
measurement, and/or in the presence of a fragility (low trauma)
fracture [9]. Due to degenerative changes at the spine with
ageing, the WHO international reference standard for osteo-
porosis diagnosis is a T-score of2.5 or less at the femoral neck
[8]. When a patient presents with a low trauma fracture, OP is a
presumptive diagnosis. BMD measurement with DXA is
advised. However, in the absence of this facility, treatment
should still be initiated (Grade C, Level IV).
Quantitative ultrasound (QUS) at the heel can predict
fragility fracture in postmenopausal women (hip, vertebral and
global fracture risk) and men over the age of 65 (hip and all
non-vertebral fractures)independently of central DXA BMD
[8] (Level III). It should not be used for the diagnosis of OP or
for monitoring treatment effects. Patients with low QUS re-
sults should be referred for BMD measurement (Grade C,
Level IV).
Bone turnover markers cannot be used for the diagnosis of
OP. However, they can provide additional information on
fracture risk and can be used to assess compliance with
treatment [10]. The International Osteoporosis Foundation
(IOF) and the International Federation of Clinical Chemistry
and Laboratory Medicine (IFCC) recommend that a marker of
bone formation (serum procollagen type I N propeptide, s-
P1NP) and a marker of bone resorption (serum C-terminal
telopeptide of type I collagen, s-CTX) be used as reference
markers for clinical studies [10] (Grade B, Level III).3.2. Assessing OP and fracture riskTable 3
Efficacy of the interventions for the prevention of osteoporosis
Intervention BMD
improvement
Decrease
vertebral
fracture rate
Decrease
hip fracture rate
Exercise A [39] e e
Calcium and
Vitamin D supplements
A [40] A [40] A [40]
Dietary calcium intake B [41] e e
Smoking cessation C e e
Reduced alcohol
consumption
C e e
Prevention of falls e e B [42]
Estrogen A [43] A [43] A [43]
Raloxifene A [44] A [45] e
Alendronate A [46] A [47] e
Tibolone A [48] A [48] eInitial investigations in a patient with OP would include a
full blood count and ESR, serum calcium and phosphate, al-
bumin, alkaline phosphatase, renal and thyroid function. Tests
for testosterone, FSH, LH, urine Bence Jones protein and
serum protein electrophoresis can be done where appropriate
(Grade C, Level IV).
Until recently, treatment thresholds for OP have been based
on BMD/T-score or the presence of a fragility fracture. Risk
factors were used to help identify people that require BMD
measurement. However, it became apparent that presence of
several of the risk factors used to trigger sending the patient
for a BMD test is associated with a fracture risk greater than
can be accounted for by BMD alone [11] (Level III). Thus, a
full OP assessment should try to integrate the clinical risk
factors and BMD to give a better fracture risk assessment than
either alone. The Fracture Risk Assessment Tool (FRAX) is
one such assessment tool that is available.
FRAX estimates the 10-year probability of hip fracture and
major osteoporotic fracture (hip, clinical spine, proximal hu-
merus or forearm) for untreated patients between the ages
40e90 years using clinical risk factors which include an in-
dividual's age, gender, weight, height, prior fracture, parental
history of hip fracture, smoking, long-term use ofglucocorticoids, rheumatoid arthritis and alcohol consumption
[12,13]. One advantage of FRAX is that BMD is not necessary
for calculation of fracture probability. If a BMD is available,
only the femoral neck BMD is to be used. BMD input from
non-hip sites has not been validated with FRAX and is
therefore not recommended [12,13] (Grade B, Level III).
The country-specific FRAX prediction algorithms are
available for some countries but not for Malaysia. For
Malaysians, we recommend the use of ethnic specific algo-
rithms (e.g. Singapore Chinese or Hong Kong, Singapore
Malay, Singapore Indian) until local data is available (Grade
C, Level IV).
The treatment interventions in FRAX have been partly
based on cost-effectiveness, for which there is no Malaysian
data. Notwithstanding that, we would propose using the Na-
tional Osteoporosis Foundation's recommended treatment
thresholds. We therefore suggest that postmenopausal women
should be considered for treatment, if they had a previous low
trauma hip, vertebral or wrist (Colles') fracture, or a T-
score  2.5 on DXA, after exclusion of secondary causes of
osteoporosis. In patients with osteopenia, initiation of treat-
ment is recommended with a fracture probability of more than
3% at 10 years for hip or 20% at 10 years for major
osteoporosis-related fracture [14] (Grade C, Level IV).
The interventions that have been shown to be useful in the
prevention of OP are shown in Table 3.3.3. Treatment of OPThe aim of treating OP is to reduce future fractures, not just
to improve BMD. Patients found to have OP should have a
careful assessment to exclude secondary causes of OP, which
should then be treated in their own right (Grade C, Level IV).
General management includes assessment of the risk of falls
and their prevention [15,16] (Grade A, Level Ia). An adequate
calcium and vitamin D intake is recommended (see discussion
below). The major pharmacological interventions available in
Malaysia are the bisphosphonates, strontium ranelate, deno-
sumab, teriparatide, raloxifene and hormone therapy (HT), all
Table 4
Efficacy of treatments available for osteoporosis. All the below treatments
have been shown in randomised controlled trials to increase bone mineral
density (Grade A)
Intervention Decrease vertebral
fracture rate
Decrease hip
fracture rate
Alendronate A [49,50] A [49,50]
Ibandronate aA [51] e
Risedronate A [52,53] A [54]
Zoledronate A [55] A [55]
Strontium Ranelate A [56] A [57]
Denosumab A [58] A [58]
r-PTH (teriparatide) A [59] e
Hormone Therapy A [43] A [43]
Tibolone A [48] e
Raloxifene A [60] e
Calcitriol/Alfacalcidol A [61,62] e
Calcium ± vitamin D A [40] A [63]
Grades corresponds to the Grades of Recommendation as in Appendix 1.
a The vertebral fracture reduction was shown with the 2.5 mg daily oral
dosing. The currently licenced ibandronate dose of 150 mg/month, has been
shown to be non-inferior to the 2.5 mg daily dose in terms of BMD gain and
bone marker suppression [64].
Table 5
Calcium content of some common Malaysian foods [65]
Food Calcium
content (mg)
1 glass of high calcium milk (200 ml) 500
1 glass of skimmed milk (200 ml) 250
1 glass of full cream milk (200 ml) 220
1 cup of yoghurt (150 g) 200
1 piece of tofu (150 g) 200
1/2 cup of yellow dhal (100 g) 170
1 cup of spinach (56 g) 160
1 cup of ice-cream (156 g) 150
1 cup of watercress (sai-yong choy) (50 g) 100
1 piece of cheddar cheese (20 g) 100
1 cup of mussels (160 g) 100
1/2 cup of anchovies (ikan bilis)
(dried without head & entrails) (20 g)
100
1 piece of canned sardine (40 g) 100
1 cup of baked beans (240 g) 100
1 cup of leafy green vegetables
(e.g. mustard green (sawi),
cekur manis, kai lan or pucuk ubi
kayu (50e80 g)
100
1 piece of tempeh (70 g) 50
1 cup of soyabean milk (200 ml) 40
1 cup of broccoli (95 g) 40
10 almonds (15 g) 30
* 1 cup ¼ 200 ml.
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given with calcium and vitamin D (Level Ia, Ib). However, not
all of them reduce hip fracture (Levels Ia, Ib). A summary of
their efficacy is shown in Table 4.
Since the last edition, there has been a re-evaluation in the
role of HT and strontium ranelate in OP treatment. HT can be
considered as a first line treatment for prevention and treat-
ment of OP in women below 60 years [17]. Initiating HT in
women after 60 years for the sole purpose of prevention of
osteoporotic fractures is not recommended [18]. Following a
review by the European Medicines Agency in 2014, assessing
the increased signal for non-fatal myocardial infarctions in the
clinical trials, they recommended that strontium ranelate
should only be used for patients with OP in whom treatment
with other medicinal products approved for the treatment of
OP is not possible [19]. Additional contra-indications for the
prescription of strontium now include established, current, or
past history of ischaemic heart disease, peripheral vascular
disease and/or cerebrovascular disease and uncontrolled hy-
pertension [19].
Furthermore, the safety of calcium and long term
bisphosphonate usage remain unresolved which will be dis-
cussed further in the following sections.
3.3.1. Calcium
For Malaysian women 50 years old or older, the recom-
mended daily calcium intake is 1,000 mg [20] (Grade C, Level
IV). This represents the total calcium intake (diet plus calcium
supplements, if applicable). Table 5 lists the calcium content
of some of the foods commonly found in Malaysia and other
parts of Asia, which may be relevant when advising Asian
patients.
Recent conflicting data suggest that excessive calcium
supplementation is associated with an increase in myocardialinfarction (MI) and cardiovascular events [21,22]. A meta-
analysis suggested that calcium supplements (on average
1,000 mg daily) taken without vitamin D increase the risk of
MI, relative risk 1.27 (95% CI 1.01e1.59) [21] (Level Ia).
Another meta-analysis of calcium or calcium and vitamin D
showed an increase in the relative risk of MI of 1.24
(1.07e1.45), p ¼ 0.004 [22] (Level Ia). In both the meta-
analyses, the average calcium intake, both from dietary
sources and supplements, was 1800 mg daily. In contrast, a
prospective randomised placebo-controlled interventional
trial on calcium carbonate 1200 mg daily showed no excess
cardiovascular risk after 5 years of follow-up, nor was there
any increase in death or hospitalization from atherosclerotic
vascular disease after another 4.5 years of the post-trial
observational study [23] (Level Ib). Another prospective
randomised trial with vitamin D 800 IU and calcium 1000 mg
daily compared to placebo showed no difference between both
groups in vascular mortality [24] (Level Ib). These results are
not directly comparable as the prospective trials examined
death, hospitalization rates and overall vascular mortality,
rather than MI. In the meta-analysis, cardiovascular events
were not the primary endpoint in the trials included, which
may have been a source of error. A recent meta-analysis of
randomised controlled trials of calcium with or without
vitamin D vs placebo showed no increase in the risk of cor-
onary heart disease (which included MI, angina pectoris,
acute coronary syndrome and chronic coronary heart disease)
with a relative risk of 1.02 (95% CI, 0.96e1.09; p ¼ 0.51)
[25].
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risk of coronary heart disease [26] (Level III). Therefore, given
the above arguments, the current recommendation is to have
adequate calcium intake from food sources [27] (Grade C,
Level IV). Optimization of vitamin D status to facilitate ab-
sorption of dietary calcium remains a sensible measure for the
maintenance of bone health [28] (Grade C, Level IV).
We recommend that the total intake of calcium is 1,000 mg
daily, both from the diet and supplements (Grade C, Level IV).
3.3.2. Vitamin D
For adults 50 years old or older, the Malaysian Recom-
mended Nutrient Intake advocates 400 IU of vitamin D per
day [20], but many experts recommend up to 800 IU per day
[28] (Grade C, Level IV). As discussed above, it would seem
that the addition of vitamin D did not reduce the elevated risk
of cardiovascular events observed with calcium supplemen-
tation [22] (Level Ia). Blood levels of 25(OH)D provide the
best index of vitamin D stores [28]. It has been suggested that
levels of 25(OH)D of >20 ng/ml (50 nmol/l) are adequate for
optimal skeletal health [28] (Grade C, Level IV). We
recommend that the intake of vitamin D is 800 IU daily, to
maintain levels of 25(OH)D at least above 20 ng/ml, and
ideally above 30 ng/ml (75 nmol/l) [29]. However, to raise the
blood level of 25(OH)D consistently above 30 ng/ml may
require at least 1500e2000 IU daily of vitamin D [29] (Grade
C, Level IV).
3.3.3. Bisphosphonates
Bisphosphonates are potent inhibitors of bone resorption
and are effective in the treatment of OP as shown in Table 4.
With increasing experience in the use of bisphosphonates, 2
adverse effects have been noted with long-term bisphospho-
nate therapy, i.e. atypical femoral fractures and osteonecrosis
of the jaw.3.4. Atypical femoral fracturesAtypical femoral fractures (AFF) have been increasingly
recognised in patients on long-term bisphosphonate therapy.
However, although current evidence has not definitely estab-
lished a causal association between bisphosphonate use and
these AFFs, the evidence for an association is quite robust [30]
(Level III).
In a meta-analysis, the overall pooled estimate of adjusted
risk ratio for AFF associated with bisphosphonates using data
from the five case-control and six cohort studies was 1.70 (95%
CI, 1.22e2.37). A large amount of heterogeneity was noted (I2
89.19%, p< 0.05) [31] (Level 1a). Although the relative risks of
AFFs are very high in patients on bisphosphonates, ranging
from 2.1 to 128, their absolute risk is extremely low, ranging
from 3.2 to 50 cases per 100,000 person-years [30] (Level III).
AFFs appear to be more common in patients who have been
exposed to long-term bisphosphonates, usually for more than 3
years (median treatment 7 years), but every series includes pa-
tients who have not been treated with bisphosphonates,suggesting that the “background rate” of AFFs in OP patients is
not zero [30] (Level III). In a study looking at Swedish women
who were on bisphosphonates, the risk of AFFs declined by
70%/year (OR 0.28; 95% CI, 0.21e0.38) after the bisphosph-
onates were stopped [32] (Level III).
Nevertheless, the benefits of bisphosphonate therapy, by
reducing classical osteoporotic fractures, outweigh the rare
risk of AFFs [30,33] (Level III).3.5. Osteonecrosis of the jawOsteonecrosis of the jaw (ONJ) can be diagnosed if all of
the following characteristics are present -current or previous
treatment with antiresorptive and/or antiangiogenic agents,
exposed bone or bone that can be probed through an
intraoral or extraoral fistula(e) in the maxillofacial region
that has persisted for more than eight weeks, and no history
of radiation therapy to the jaws or obvious metastatic disease
to the jaws [34]. Classical risk factors for development of
ONJ include dentoalveolar surgery, periodontal disease,
trauma, poorly fitting dentures, obesity, smoking, and
glucocorticoid and high-dose IV bisphosphonate therapy
[35] (Level IV).
The frequency of ONJ in osteoporotic patients is rare,
ranging from 1.04 to 69 per 100,000 patient-years in those on
oral bisphosphonates to 0e90 per 100,000 patient-years for
those on IV bisphosphonates [35] Level III). The best current
estimate for the risk of ONJ among patients exposed to oral
bisphosphonates following tooth extraction is 0.5% [36](Level
III).
For patients receiving oral bisphosphonate therapy to
manage OP, the prevalence of ONJ increases over time from
near 0 at baseline to 0.21% after four or more years of
bisphosphonate exposure. The median duration of
bisphosphonate exposure for patients with ONJ and ONJ-like
features was 4.4 years [34] (Level III). As a guide, for in-
dividuals who have taken an oral bisphosphonate for less
than four years and have no clinical risk factors, no alteration
or delay in any elective invasive dental surgery is necessary.
For those who have taken more than 4 years of bisphosph-
onate treatment, consider discontinuation of the oral
bisphosphonate (drug holiday) for at least two months prior
to oral surgery, if systemic conditions permit. The anti-
resorptive should not be restarted until osseous healing has
occurred [34] (Level IV).3.6. Guidelines for use of bisphosphonatesWith the above in mind, it is recommended that patients
who are deemed to be at low risk of osteoporosis-related
fractures should not be started on bisphosphonates [30].
The efficacy of bisphosphonate therapy should be evalu-
ated after 3e5 years [37]. If a lack of efficacy is noted,
i.e. significant deterioration of BMD, or recurrent low
trauma fracture, re-evaluation is required to exclude the
following:
Fig. 1. Algorithm for the management of postmenopausal osteoporosis. Abbreviations for Fig. 1. BMD¼Bone mineral density, BTM¼Bone turnover markers,
FRAX¼ Fracture Risk Assessment Tool, HT¼Hormone therapy, OSTA¼Osteoporosis Self-Assessment Tool for Asians, r-PTH¼Recombinant parathyroid
hormone, SERM¼ Selective estrogen receptor modulator, STEAR¼ Selective tissue estrogenic activity regulator.
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2. Drug compliance
If the above have been excluded, bisphosphonates can
either be continued or an alternative therapy can be considered
(i.e. anabolic therapy).
When prescribing bisphosphonates for longer than 5 years,
evaluation of the need for continued bisphosphonate therapy is
recommended every 2e3 years. In patients with:
 a low risk of fracture, consider a drug holiday evidence of AFF, bisphosphonate therapy should be
discontinued
 a high risk of fracture, consider continuing bisphosphonate
therapy, up to 10 years [38].
(Grade C, Level IV)3.7. Algorithm for the treatment of postmenopausal OPFollowing clinical assessment, all patients should be
advised on general measures to improve bone health. In
Fig. 2. Algorithm for the management of male osteoporosis. **Bone Profile ¼ Calcium, phosphate, alkaline phosphatase, albumin, creatinine, ESR ¼ Erythrocyte
Sedimentation Rate, TSH ¼ Thyroid Stimulating Hormone.
7S.S. Yeap et al. / Osteoporosis and Sarcopenia 2 (2016) 1e12patients who have already had a prior low trauma/fragility
fracture, without any cause to suggest secondary OP, treatment
can be started; measurement of BMD is ideal if available. For
those with risk factors but no prior fracture, assessment using
the FRAX tool is suggested. This can be used with or without
a BMD measurement. In patients found to have a high 10-year
risk of fracture with FRAX, treatment should be started. In
patients with a low risk of fracture, BMD can be measured and
monitored at 1e2 yearly intervals. If FRAX is not available,
and there is still concern about the possibility of OP, a BMD
measurement can be obtained. Patients with a T score  2.5
have OP and should be started on treatment. Patients withosteopenia (T-score between 1.0 and 2.5) can be treated if
there are multiple risk factors present, and a FRAX assessment
is not available. Patients with a normal T-score (>1.0) can be
monitored with 1e2 yearly BMD measurements. The sug-
gested pathway for the management of postmenopausal OP is
shown in Fig. 1.4. Male osteoporosis
Men account for up to 30% of hip fractures and 20% of
clinical vertebral fractures [66] (Grade B, Level III). In 50% of
8 S.S. Yeap et al. / Osteoporosis and Sarcopenia 2 (2016) 1e12osteoporotic men, an underlying cause can be identified
(secondary OP) [66].
Management consists of identifying and treating underlying
causes. Androgen treatment is beneficial in hypogonadal men
[67]. The following have been shown to increase BMD in men
with OP - once weekly alendronate [68], once weekly risedr-
onate [69], once monthly ibandronate [70], IV zoledronate
[71], teriparatide (r-PTH) [72], denosumab [73] and strontium
ranelate [74], but only alendronate [68] and risedronate [75]
have been shown to reduce vertebral fracture (Grade A,
Level Ib). The suggested pathway for the management of male
OP is shown in Fig. 2.
The key recommendations are summarised in Appendix 3.
In conclusion, we hope that this guidance document will
help health care practitioners when making clinical decisionsAppendix 1.
Levels of evidence and grades of recommendation.
Levels of evidence
Levels Type of evidence
Ia Evidence obtained from meta-analysis of ra
Ib Evidence obtained from at least one RCT
IIa Evidence obtained from at least one well d
IIb Evidence obtained from at least one other t
III Evidence obtained from well-designed non-
case-control studies
IV Evidence obtained from expert committee r
Used by the National Guideline Clearinghouse (www.guidelines.gov), Agency for H
USA [4].
Grades of recommendation
Grade Recommendation
A (evidence levels Ia and Ib) Requires at least one randomized controlled t
consistency addressing the specific recommen
B (evidence levels IIa, IIb and III) Requires availability of well conducted clinic
recommendation.
C (evidence level IV) Required evidence obtained from expert comm
Indicates absence of directly applicable clinic
Modified from the Scottish Intercollegiate Guidelines Network (SIGN) [5].on managing their patients with OP. This article is not meant
to be a comprehensive review of all aspects of OP, neither is
it prescriptive; it is meant to be a short but practical and
relevant guide through the OP literature, with final decisions
made after consideration of the individuals' benefits and
risks.Conflicts of interest
All the authors of this guidance have declared no conflicts
of interest. The development of this guidance was fully funded
by MOS.ndomised controlled trials (RCTs)
esigned controlled study without randomisation
ype of well-designed quasi-experimental study
experimental descriptive studies e.g. comparative studies, correlation studies,
eports or opinions and/or clinical experience of respected authorities, or both
ealthcare Research and Quality, U.S. Department of Health& Human Services,
rial as part of the body of literature of overall good quality and
dation.
al studies but no randomized clinical trials on the topic of
ittee reports or opinions and/or clinical experiences of respected authorities.
al studies of good quality.
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Implications Recommendation
High risk 61% will have OP on BMD measurement Suggest to measure BMD and consider pharmacologic treatment if BMD is not available,
especially if other risk factors are present
Medium risk 15% will have OP on BMD measurement Suggest measure BMD and consider pharmacologic treatment if BMD is low
Low risk 3% will have OP on BMD measurement BMD measurement is usually not necessary unless other risk factors are present
BMD: bone mineral density, OP: osteoporosis.Appendix 3.Key RecommendationsIn those with a low trauma fracture, a BMD measurement,
though advisable, is not necessary before starting therapy.
(Grade C, Level IV)
In addition to the diagnosis of osteoporosis, there should be
fracture risk assessment and exclusion of secondary causes
of osteoporosis.
(Grade C, Level IV)
BMD measurement is recommended especially when
assessment would influence management and may save
more resources than undirected use of treatment in all
patients.
(Grade C, Level IV)
The gold standard for measuring BMD is dual-energy x-ray
absorptiometry (DXA). DXA still remains the recommendedmethod in the diagnosis of osteoporosis and monitoring the
effect of therapy. Other methods for measuring BMD such as
quantitative computed tomography (QCT) and quantitative
ultrasound (QUS) are not recommended for diagnosing
osteoporosis but QUS may help in case-finding.
(Grade C, Level IV)
FRAX is a fracture risk assessment tool used to evaluate the
10-year probability of hip and major osteoporotic fracture
risk that integrates clinical risk factors and bone mineral
density at the femoral neck in its calculations. Until more
Malaysian data are available, it is recommended to use the
Singapore prediction algorithm.
(Grade B, Level III)
OSTA can be used to screen postmenopausal women for
further assessment of osteoporosis.
(Grade B, Level III)
Population-based strategies for the prevention of osteopo-
rosis include life-style modification such as adequate cal-
cium and vitamin D intake, exercise, reducing smoking and
10 S.S. Yeap et al. / Osteoporosis and Sarcopenia 2 (2016) 1e12alcohol intake, for those at risk. The evidence for the effi-
cacy of these preventative measures is shown in Table 3.
(Grade C, Level IV)
The recommended daily intake for calcium is 1000 mg
(both from dietary sources and supplements) and for
vitamin D is 800 IU.
(Grade C, Level IV)
After assessment, treatment can be considered for post-
menopausal women if they had a previous low trauma hip,
vertebral or wrist fracture, or have a T-score  2.5. In
patients with osteopenia, initiation of treatment is recom-
mended with a FRAX® fracture probability of more than 3%
for the hip or 20% formajor osteoporotic fracture at 10 years.
(Grade C, Level IV)
The evidence for the efficacy of medications available for
the treatment of OP is shown in Table 4. The choice of drug
for established osteoporosis, especially those with previous
fracture must be an agent shown not only to increase BMD,
but also proven to reduce fracture both at the spine and hip.
(Grade C, Level IV)
Hip fractures should be surgically managed promptly to
allow early ambulation. Spine and wrist fractures may need
operative intervention.
(Grade C, Level IV)
Secondary causes of osteoporosis should be excluded in
men. Bisphosphonates, PTH, denosumab and strontium
have been shown to be effective, and androgen is useful in
hypogonadal men.
(Grade A, Level Ib)References
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